BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.

GRI Bio, Inc. today announced that Marc Hertz, PhD, President and Chief Executive Officer will participate in a fireside chat at Benzinga’s Virtual Biotech Conference on Thursday, August 3, 2023 at 11:15 AM ET.

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study.

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs.

Quanta Dialysis Technologies® today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication of the Quanta Dialysis System, a compact and easy-to-use hemodialysis device, for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF).

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is covered, as of August 1, 2023, under the Alberta Drug Benefit List for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) announces, that a notice of requisition of a general meeting of shareholders (the “Requisition”) was delivered to the registered office of the Company on July 24, 2023.

The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZeneca’s Beyfortus™ for the prevention of respiratory syncytial virus lower respiratory tract disease for newborns and infants below 8 months of age born during or entering their first RSV season.

Invivyd, Inc. announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent business highlights.